Gordon McVie

  • Gordon McVie

Professor Gordon McVie is an international authority on the treatment and research of cancer. Along with Umberto Veronesi he is the founding editor of ecancermedicalscience, an open access cancer journal from the European Institute of Oncology in Milan.

He has written over 300 peer-reviewed papers and editorials as well as contributing to numerous books. He currently serves on several committees including the American Association for Cancer Research and the American Society of Clinical Oncology. He also serves on the boards of the National Cancer Institutes of France, Italy and the Netherlands. In the UK, he has been on the boards of cancer institutes in Glasgow, Manchester and London.

He is currently Director of Cancer Intelligence, providing advisory services to the media, patients, pharmaceutical and biotechnology companies as well as publishing ecancermedicalscience. McVie is a Senior Consultant at the European Institute of Oncology, Visiting Professor at Glasgow University, in Scotland, and Honorary Consultant in Medical Oncology at the Welsh Cancer Institute, Cardiff, Wales.
He has formulated several substantial additions to the field of cancer care including establishing localised, more pin-point, administration of chemotherapy, and encouraging the use of chemotherapy for the treatment of lung cancer throughout the EU. He has also emphasised the importance of adjusting a patient’s management according to their ethnicity.

McVie obtained his PhDs in science and medicine at Edinburgh University, and was appointed Foundation Senior Lecturer at the Cancer Research Campaign Oncology Unit (currently Beatson West of Scotland Cancer Centre) at the University of Glasgow. Under Gordon Hamilton-Fairley, he trained in the United States, spending sabbaticals in Paris, Sydney, Australia and Amsterdam.

During the 1980s, McVie spent time as a Consultant in Oncology at the Antoni van Leewenhoek hospital in Amsterdam. Throughout his time in the Netherlands he was also Clinical Research Director at the National Cancer Institute of the Netherlands. From this position he helped to establish the drug development office of the European Organisation for Treatment and Research into Cancer (EORTC). As President of EORTC, he set up the present Drug Development Group in Brussels, and with NCI support, the European New Drug Development Network. In the UK he was one of the architects of the Cancer Trials Networks in Scotland, Wales, and England, and was a founding member of the National Cancer Research Institute.
He was Director General of Cancer Research UK (CRUK), the largest cancer charity in the UK, from 1996 to 2002. During this time over 60 new drugs were taken from laboratory to clinical trial.